Johnson FR, Ozdemir F, Mansfield CA, Hass S, Miller DP, Siegel CA, Sands BE. Crohn's disease patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007 Sep;133(3):769-79.
Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28(5):264-82.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of chronic oral dosing of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory activity. Gastroenterology. 1992;102(4):A50.
Ciociola AA, Koch KM, McSorley DJ. Safety and pharmacokinetics of ascending oral doses of gr122311x (ranitidine bismuth citrate), a new bismuth compound with anti-secretory properties. Gastroenterology. 1992;102(4):A51.